Skip to main content
Clinical Trials/NCT04556149
NCT04556149
Completed
Not Applicable

SARS-CoV-2/COVID-19 Study of the Audible and Inaudible Vibroacoustic E-stethoscope - imPulse™ Una

Level 42 AI, Inc.1 site in 1 country34 target enrollmentOctober 1, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Corona Virus Infection
Sponsor
Level 42 AI, Inc.
Enrollment
34
Locations
1
Primary Endpoint
Diagnostic performance characteristics
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

This study generates robust clinical data to train ML/AI algorithms of the Sponsor's imPulse™ Una full-spectrum e-stethoscope for digital diagnostic feature synthesis of symptomatic SARS-CoV-2/COVID-19 biosignatures for rapid and accurate mass screening.

Detailed Description

This study is designed to evaluate the ability of the imPulse™ Una e-stethoscope to differentiate vibroacoustic signals in inpatients with and without confirmed COVID-19 as the first step to establish the performance characteristics - sensitivity, specificity, positive and negative predictive value - of the imPulse™ Una device for early and rapid, point-of-care diagnosis of COVID-19. This will inform the utility and design of further larger-scale studies using the device.

Registry
clinicaltrials.gov
Start Date
October 1, 2020
End Date
December 2, 2020
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Diagnostic performance characteristics

Time Frame: through study completion, an average of 2 weeks

Sensitivity, specificity, positive and negative predictive values - of the imPulse™ Una device for point-of-care diagnosis of COVID-19.

Study Sites (1)

Loading locations...

Similar Trials